- Home
- AIM vs EVGN Comparison
AIM vs EVGN Comparison
Compare AIM & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- EVGN
- Stock Information
- Founded
- AIM 1966
- EVGN 1999
- Country
- AIM United States
- EVGN Israel
- Employees
- AIM N/A
- EVGN N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- EVGN Agricultural Chemicals
- Sector
- AIM Health Care
- EVGN Industrials
- Exchange
- AIM Nasdaq
- EVGN Nasdaq
- Market Cap
- AIM 9.8M
- EVGN 9.7M
- IPO Year
- AIM N/A
- EVGN N/A
- Fundamental
- Price
- AIM $0.14
- EVGN $1.42
- Analyst Decision
- AIM Strong Buy
- EVGN Strong Buy
- Analyst Count
- AIM 2
- EVGN 1
- Target Price
- AIM $2.75
- EVGN $12.00
- AVG Volume (30 Days)
- AIM 1.5M
- EVGN 21.1K
- Earning Date
- AIM 04-01-2025
- EVGN 03-06-2025
- Dividend Yield
- AIM N/A
- EVGN N/A
- EPS Growth
- AIM N/A
- EVGN N/A
- EPS
- AIM N/A
- EVGN N/A
- Revenue
- AIM $190,000.00
- EVGN $7,478,000.00
- Revenue This Year
- AIM N/A
- EVGN $90.35
- Revenue Next Year
- AIM $1,693.10
- EVGN $38.71
- P/E Ratio
- AIM N/A
- EVGN N/A
- Revenue Growth
- AIM N/A
- EVGN 30.69
- 52 Week Low
- AIM $0.12
- EVGN $1.20
- 52 Week High
- AIM $0.62
- EVGN $10.40
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- EVGN 42.28
- Support Level
- AIM $0.12
- EVGN $1.44
- Resistance Level
- AIM $0.21
- EVGN $1.55
- Average True Range (ATR)
- AIM 0.02
- EVGN 0.09
- MACD
- AIM -0.00
- EVGN -0.01
- Stochastic Oscillator
- AIM 22.88
- EVGN 17.41
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.